Health related quality of life, treatment satisfaction and costs associated with intraperitoneal versus subcutaneous insulin administration in type 1 diabetes. A randomized controlled trial
- Susan J. Logtenberg, MD (s.j.j.logtenberg{at}isala.nl)1,
- Nanne Kleefstra, MD1,2,
- Sebastiaan T. Houweling, MD, PhD1,2,3,
- Klaas H. Groenier, PhD4,5,
- Reinold O. Gans, MD, PhD5,6 and
- Henk J. Bilo, MD, PhD, FRCP1,5,6
- 1. Diabetes Centre, Isala Clinics, Zwolle, The Netherlands
- 2. Langerhans Medical Research Group, The Netherlands
- 3. General Practice Sleeuwijk, the Netherlands
- 4. Department of General Practice, University Medical Center Groningen, Groningen, The Netherlands
- 5. University of Groningen, Groningen, The Netherlands
- 6. Department of Internal Medicine, University Medical Center Groningen, Groningen, The Netherlands
Abstract
Objective- To investigate the effects of continuous intraperitoneal insulin infusion (CIPII) compared to subcutaneous insulin on health related quality of life (HRQOL) and treatment satisfaction, and to perform a cost analysis in type 1 diabetes.
Research Design and Methods- Open-label, prospective, crossover, randomized, 16-month study (n=24). HRQOL and patient satisfaction were assessed with questionnaires (SF-36, WHO-5 and DTSQ, respectively). Direct costs of CIPII and continuous subcutaneous insulin infusion (CSII) were compared.
Results- Questionnaires scores were higher with CIPII compared to subcutaneous therapy. Yearly direct pump- and procedures associated costs for CIPII were estimated at €10,910 compared to €4,810 for CSII.
Conclusions- Apart from improving glycemic control, CIPII improved HRQOL and treatment satisfaction as compared to subcutaneous insulin. Direct pump- and procedures associated costs are considerably higher, however.
Footnotes
-
- Received September 21, 2009.
- Accepted February 16, 2010.
- Copyright © American Diabetes Association














